October 27, 2020

CaroGen and Wayne State University scientists report significant progress on development of CARG-2020 for the potential treatment of ovarian cancer

Farmington, Conn., Oct. 25, 2020 – Privately-held CaroGen Corp., in collaboration with a team of scientists at the C.S. Mott Center for Human Growth and Development at Wayne State University, today announced that they have made significant progress in developing CARG-2020 for potential treatment of patients with ovarian cancer and other peritoneal tumors.

“We have shown through a number of in vitro and in vivo experiments that CARG-2020-delivering multiple immunomodulators induce broad spectrum immune re-sponses, resulting in prevention of tumor recurrence and curing the mice with ovarian cancer. CARG-2020 is a potent therapy and could potentially be a game-changer in the field of ovarian cancer immune-oncology. In addition to ovarian cancer, CARG-2020 has the potential to be used as a therapeutic approach for other peritoneal solid tumors,” said Gil Mor, M.D., Ph.D., director of the Mott Center and the John M. Malone Jr., M.D., Endowed Professor of Obstetrics and Gynecology at Wayne State University. Dr. Mor serves as a member of CaroGen’s Scientific Advisory Board.

“CARG-2020, based on the patented AVIDIO (Artificial Virus for Infectious Diseases and Immune-Oncology) technology platform, is an oncolytic vector that delivers an RNA expressing three immuno-modulators, and therefore, working through multiple pathways, induces potent and durable responses in animal models of colorectal and ovarian cancer,” said Bijan Almassian, Ph.D., chief executive officer and co-founder of CaroGen Corp. “We are delighted to collaborate with Professor Mor, a prominent immunologist, to work on the discovery of a novel immunotherapy for ovarian cancer. Our collaboration with Dr. Mor began in 2018 when he was a tenured professor at Yale University School of Medicine.”

Ovarian cancer accounts for most deaths from gynecologic malignancies. Although more than 80% of patients respond to first-line standard of care chemotherapy, most present with recurrence and eventually succumb to carcinomatosis and chemothera-py-resistant disease. To improve patient survival, new modalities are necessary to tar-get residual disease and consequently prevent recurrence.

About CaroGen Corporation

CaroGen, based in Farmington, Conn., is creating a portfolio of immunotherapies and vaccines for oncology and infectious diseases using its patented AVIDIO immunother-apy platform, discovered at Yale University School of Medicine by renowned virologist John Rose, Ph.D., and licensed by CaroGen for worldwide use. CaroGen’s initial focus has been on developing a potential functional cure for chronic HBV infection. CaroGen has completed preclinical proof-of-concept in HBV animal models and selected a clin-ical candidate, CARG-201. CaroGen also is exploiting its AVIDIO platform technology to create novel immunotherapies for colorectal, ovarian and liver cancers in collabora-tions with medical researchers at Yale University, the University of Connecticut, Wayne State University and Brown University. CaroGen also is developing a COVID-19 vaccine in collaboration with Yale School of Medicine scientists.


About Wayne State University

Wayne State University is a premier urban research institution offering more than 350 academic programs through 13 schools and colleges to nearly 27,000 students.



Bijan Almassian, Ph.D. President and CEO, CaroGen Corporation